Newsroom 2007
- December 14, 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis...
- December 6, 2007
Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review..
- November 30, 2007
Neurochem announces departure of Dr. Philippe Calais, President, Global Business...
- November 8, 2007
Neurochem announces important initiatives to provide medical and health benefits to patients...
- November 7, 2007
Neurochem reports results for third quarter of fiscal 2007...
- August 28, 2007
Neurochem provides information on cash position...
- August 26, 2007
Neurochem Announces results from Tramiprosate (ALZHEMED(TM)) North American Phase III Clinical Trial...
- August 9, 2007
Neurochem reports results for second quarter of fiscal 2007...
- July 24, 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))...
- July 17, 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis...
- June 26, 2007
Neurochem to present at Jefferies Healthcare Conference
- June 22, 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update LAVAL, QC, June 22 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
has issued an update on the...
- June 21, 2007
Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM)) LAVAL, QC, June 21 /CNW Telbec/ -...
- June 18, 2007
Neurochem Announces Mandatory and Full Conversion of All Outstanding Senior Subordinated Convertible Notes
Neurochem Announces Mandatory and Full Conversion of All Outstanding Senior Subordinated Convertible Notes LAVAL, QC, June 18 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)
...
- June 11, 2007
At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (ALZHEMED(TM))
At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (ALZHEMED(TM)) ...
- June 7, 2007
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis ECUBLENS,...
- June 5, 2007
Neurochem announces it has obtained written consent from its shareholders in connection with its private placement of US$80 million aggregate principal amount of convertible notes...
- May 8, 2007
At Annual General Meeting of Shareholders (AGM) - Neurochem provides update on core product candidates and recent financing of us$80 million...
- May 8, 2007
Neurochem reports results for first quarter of fiscal 2007...
- May 7, 2007
Media advisory - Neurochem's Annual General Meeting of Shareholders on May 8, 2007...
- May 2, 2007
Neurochem Announces Private Placement of US$80 Million Aggregate Principal Amount of 6% Senior Convertible Notes and 5% Senior Subordinated Convertible Notes...
- April 19, 2007
Neurochem Update on the North American Phase III Clinical Trial for Tramiprosate (ALZHEMED(TM)) for the Treatment of Alzheimer's Disease...
- April 11, 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA...
- February 21, 2007
Neurochem reports results for fourth quarter and fiscal year 2006...
- February 13, 2007
Neurochem receives second recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))...
- February 1, 2007
Neurochem announcement regarding the completion of its North American phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease...
- January 17, 2007
Neurochem files shelf prospectus in connection with previously announced equity line of credit facility and convertible notes financings...
- January 16, 2007
Neurochem announces appointment of John Bernbach to Board of Directors...
- January 4, 2007
Neurochem to present at JPMorgan Healthcare Conference...
|
